Oncology
09/2016

Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients

Precison: Lung Cancer R&D Summit
Read More
Oncology
08/2016

DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics

Journal of Cell Signaling
Read More
Oncology
06/2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

ASCO Annual Meeting
Read More
Oncology
04/2016

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study

AACR Annual Meeting
Read More
Oncology
04/2016

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640

AACR Annual Meeting
Read More
Oncology
03/2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640

International Congress on Targeted Anticancer Therapies
Read More
Oncology
02/2016

Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement

Keystone Symposium - New Frontiers in Understanding Tumor Metabolism
Read More
Oncology
02/2016

Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement

Keystone Symposium - New Frontiers in Understanding Tumor Metabolism
Read More
Oncology
11/2015

A First in Human Study of the First in Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640. Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity

EORTC-NCI-AACR International Conference
Read More
Oncology
11/2015

Biomarker Analyses from Dose Escalation and Expansion Phases of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients

EORTC-NCI-AACR International Conference
Read More